DLC1 and gastric cancer: Thus, DLCv4, lacking the auto-inhibitory N-terminal domain and/or harbouring other unidentified mutations [20], may gain aberrant oncogenic function in gastric cells, a feature which could explain the observed enrichment of DLC1 mRNA/protein in diffuse-type (CMS2) and advanced stages of GC with distant metastases [6].